Research Highlights: Clinical relevance of the type I interferon signature in multiple sclerosis

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.16, 2012-12, pp. : 1883-1885

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Commentary: (Research Highlights Inflammation, Demyelination and Neurodegeneration: Risky Buddies in Multiple Sclerosis)

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 1, 2014-02 ,pp. : 4-5

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Gains in Clinical Multiple Sclerosis Research

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 5, 2012-08 ,pp. : 497-505

Bentham Science Publishers

Access to resources Recommend Favorite

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

Arthritis & Rheumatism, Vol. 62, Iss. 12, 2010-12 ,pp. : 3607-3614

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon-Beta in the Treatment of Multiple Sclerosis: Do Clinical Data Support the Existence of a Ceiling Effect?

By Clanet M.

Clinical Drug Investigation, Vol. 21, Iss. 4, 2001-04 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite

Hepatic Reactions During Treatment of Multiple Sclerosis with Interferon- -1a: Incidence and Clinical Significance

By Francis G.S.

Drug Safety, Vol. 26, Iss. 11, 2003-01 ,pp. : 815-827

Adis International

Access to resources Recommend Favorite